An Open-label, Multicenter Study to Assess the Long -Term Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain
Phase of Trial: Phase III
Latest Information Update: 14 May 2016
At a glance
- Drugs Hydrocodone (Primary)
- Indications Pain
- Focus Adverse reactions; Registrational
- Sponsors Purdue Pharma
- 14 May 2016 Post- hoc results presented at the 35th Annual Scientific Meeting of the American Pain Society
- 13 May 2015 According to a Purdue media release, data from this study were presented at the 34th Annual American Pain Society Scientific Meeting 2015.
- 29 Apr 2014 Results will be presented at the American Pain Society 33rd Annual Scientific Meeting, according to a Purdue media release.